Show Summary Details
Page of

Biochemistry of Duchenne muscular dystrophy 

Biochemistry of Duchenne muscular dystrophy
Biochemistry of Duchenne muscular dystrophy

Alan E H Emery

, Francesco Muntoni

, and Rosaline Quinlivan

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 31 July 2021

The literature on the biochemistry of muscular dystrophy is overwhelming. It could be argued that, now that the primary defect has been identified in DMD and shown to be a deficiency of muscle dystrophin, it is irrelevant to approach an understanding of the pathogenesis through the findings of conventional biochemistry. The authors feel that molecular and biochemical studies could complement each other. What has been learned so far concerning biochemical changes in dystrophic muscle and how these relate to the deficiency of dystrophin will doubtless fill in details of how the disease process starts and progresses, and why it affects some muscles more than others. It is also conceivable that the more we know of the detailed pathogenesis of DMD, the more we may understand these processes in other muscular dystrophies. With such details, it may be possible to better consider a rational approach to any drug therapy.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.